Surgery or Biologic for Nasal Polyps? A Close Look at the Evidence

Target Audience
The intended audience for this program is ENTs, allergists, immunologists, specialty nurse practitioners and PAs, and other clinicians involved in the management of patients with nasal polyps.

Program Overview
As management strategies for nasal polyps (NPs) have evolved, patients whose NPs do not respond to initial treatment, who are ineligible for systemic corticosteroids, or whose NPs recur after initial surgery often undergo repeated surgeries, with high associated costs and complication risks. Clinicians"including ear, nose, and throat specialists (ENTs) and allergists"need to be aware of the latest strategies to personalize NP care and establish personalized treatment plans with the lowest risk of recurrence, toward improving patients’ overall quality of life, including their ability to breath and smell.

Join an expert panel of ENTs to explore the underlying pathways that lead to NPs and drive recurrent disease and treatment resistance. Panelists will also discuss the burdens faced by patients with NPs and evidence supporting the efficacy and safety of biologic agents for the treatment of refractory and recurrent NPs.

Do you have patients with NPs who could benefit from education on biologic treatment options? Direct your patients to MedLive.com to access the activity, “Making Your Voice Heard: Could Your Nasal Polyps Benefit from a Biologic Medicine?”

Learning Objectives
After completing this activity, the participant should be better able to:

Describe the inflammatory relationships between NPs and common T2-driven comorbidities
Discuss safety, efficacy, and impacts on bothersome symptoms of current targeted therapies for patients with moderate-to-severe CRSwNP
Review patient-specific factors that help predict NP recurrence after standard treatment, including surgery